Literature DB >> 11995488

Dietary iron restriction improves aminotransferase levels in chronic hepatitis C patients.

Motoh Iwasa1, Masahiko Kaito, Jiro Ikoma, Yoshinao Kobayashi, Yuji Tanaka, Kunihiro Higuchi, Keisuke Takeuchi, Kazuko Iwata, Shozo Watanabe, Yukihiko Adachi.   

Abstract

BACKGROUND/AIMS: It is generally accepted that iron overload plays an important role in the pathogenesis of liver cell injury in chronic hepatitis C. The present study was undertaken to evaluate whether low-iron diet improves liver function tests in patients with chronic hepatitis C.
METHODOLOGY: Seventeen patients with chronic hepatitis C (13 men and 4 women, 54 +/- 14 years old) that did not respond to, or were unsuitable for interferon therapy, were enrolled in this study. All patients had been pretreated with ursodeoxycholic acid for more than 12 months before the beginning of the study. Dietary iron intake was restricted to less than 7 mg/day, and the patients were followed up for 18 months.
RESULTS: Mean daily iron intakes, calculated from food records, were 5.9 and 6.4 mg after 6 and 12 months, respectively. The mean serum ferritin decreased significantly from 362 ng/mL at entry to 179 ng/mL after 18 months. The serum unsaturated iron binding capacity level increased significantly from 163 micrograms/dL at entry to 203 micrograms/dL after 18 months. The serum aspartate aminotransferase decreased significantly from 62 IU/L at entry to 47 IU/L after 18 months, and serum alanine aminotransferase from 68 IU/L at entry to 53 IU/L after 18 months. Serum iron, hepatitis C virus-RNA titer and platelet count remained unchanged throughout the study.
CONCLUSIONS: These results suggest that iron-restricted diet may be an important therapeutic modality for improving liver injury in patients with chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11995488

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  7 in total

1.  Molecular mechanism of iron metabolism and overload in chronic hepatitis C.

Authors:  Masahiko Kaito
Journal:  J Gastroenterol       Date:  2007-01       Impact factor: 7.527

2.  Iron, haemochromatosis and thalassaemia as risk factors for fibrosis in hepatitis C virus infection.

Authors:  Mark Thursz
Journal:  Gut       Date:  2007-05       Impact factor: 23.059

3.  Iron, hepatitis C virus, and hepatocellular carcinoma: iron reduction preaches the gospel for chronic hepatitis C.

Authors:  Naoki Fujita; Yoshiyuki Takei
Journal:  J Gastroenterol       Date:  2007-11       Impact factor: 7.527

Review 4.  HCV and oxidative stress in the liver.

Authors:  Alexander V Ivanov; Birke Bartosch; Olga A Smirnova; Maria G Isaguliants; Sergey N Kochetkov
Journal:  Viruses       Date:  2013-01-28       Impact factor: 5.048

5.  Nutrition therapy for liver diseases based on the status of nutritional intake.

Authors:  Kenichiro Yasutake; Motoyuki Kohjima; Manabu Nakashima; Kazuhiro Kotoh; Makoto Nakamuta; Munechika Enjoji
Journal:  Gastroenterol Res Pract       Date:  2012-11-14       Impact factor: 2.260

6.  Treatment Options for Hepatitis C Infection in Children.

Authors:  Aymin Delgado-Borrego; Maureen M. Jonas
Journal:  Curr Treat Options Gastroenterol       Date:  2004-10

7.  Hemoglobin Decrease with Iron Deficiency Induced by Daclatasvir plus Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b.

Authors:  Nobuyuki Matsumoto; Hiroki Ikeda; Ryuta Shigefuku; Nobuhiro Hattori; Tsunamasa Watanabe; Kotaro Matsunaga; Tetsuya Hiraishi; Tomohiro Tamura; Yohei Noguchi; Yasunobu Fukuda; Toshiya Ishii; Chiaki Okuse; Akira Sato; Michihiro Suzuki; Fumio Itoh
Journal:  PLoS One       Date:  2016-03-18       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.